| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antiangiogenic therapy in the management of brain tumors: a clinical overview
|
Kunnakkat, Saroj
|
|
2012
|
70 |
3 |
p. 353-363
|
artikel
|
| 2 |
Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation
|
Ren, Shuai
|
|
2012
|
70 |
3 |
p. 415-424
|
artikel
|
| 3 |
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
|
Jones, Suzanne F.
|
|
2012
|
70 |
3 |
p. 471-475
|
artikel
|
| 4 |
AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts
|
Iyer, Radhika
|
|
2012
|
70 |
3 |
p. 477-486
|
artikel
|
| 5 |
Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways
|
Li, Xiuxia
|
|
2012
|
70 |
3 |
p. 425-437
|
artikel
|
| 6 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
|
Togashi, Yosuke
|
|
2012
|
70 |
3 |
p. 399-405
|
artikel
|
| 7 |
Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis
|
Kojima, Yuki
|
|
2012
|
70 |
3 |
p. 391-397
|
artikel
|
| 8 |
Dose escalation and pharmacokinetic study of nanoparticle curcumin… by Kanai et al., CCP 69:65–70, 2012
|
Gescher, Andreas J.
|
|
2012
|
70 |
3 |
p. 487
|
artikel
|
| 9 |
Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer
|
Han, Li
|
|
2012
|
70 |
3 |
p. 365-372
|
artikel
|
| 10 |
In response
|
Kanai, Masashi
|
|
2012
|
70 |
3 |
p. 489
|
artikel
|
| 11 |
Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
|
Aoyama, Yumiko
|
|
2012
|
70 |
3 |
p. 373-380
|
artikel
|
| 12 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer
|
Kim, Jae-Sung
|
|
2012
|
70 |
3 |
p. 381-389
|
artikel
|
| 13 |
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
|
Dennis, Mike
|
|
2012
|
70 |
3 |
p. 461-469
|
artikel
|
| 14 |
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
|
Murakami, Haruyasu
|
|
2012
|
70 |
3 |
p. 407-414
|
artikel
|
| 15 |
Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates
|
Gianolio, Diego A.
|
|
2012
|
70 |
3 |
p. 439-449
|
artikel
|
| 16 |
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis
|
Miyata, Yasuyoshi
|
|
2012
|
70 |
3 |
p. 451-459
|
artikel
|
Tijdschrift beschrijving